- $106.34bn
- $123.47bn
- €46.72bn
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes
Sanofi ends Phase 3 riliprubart trial after weak interim results
Brief: Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In CIDP
AI coding startup Cursor, courted by SpaceX, picks London as European hub
Brief: Sanofi: EC Approves Sarclisa
Brief: Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi
Brief: UK's MHRA Approves Rilzabrutinib To Treat Adults With Immune Thrombocytopenia
Corrected: BRIEF-Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28)
US FDA advisers vote in favor of recommending COVID vaccines target XFG variant
FDA advisers recommend COVID vaccines be updated to target current dominant variant (updated)
FDA advisers to weigh composition of COVID vaccines for 2026-2027
Brief: Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of MG3
US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant (updated)
US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant
China's commerce ministry holds meeting with foreign pharmaceutical firms
Brief: Sanofi's rare lung disease drug outperforms standard care in trial